Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry

Abstract

In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 1930 patients registered in the Danish Neuro-Oncology Registry (DNOR) from 2009 to 2014. DNOR is a large-scale national population-based database including all adult glioma patients in Denmark. The age-adjusted annual incidence of histologic verified glioma was 7.3 cases pr. 100,000 person-years. High-grade gliomas were present in 85% and low-grade glioma in 15%. The overall male:female ratio was 3:2 and the mean age at onset was 60 years. Data for WHO grade I, II, III and IV glioma showed several important differences regarding age and sex distribution and symptomatology at presentation. The mean age increased with the grade of glioma and males predominated in all grades. Focal deficits were the most frequent presenting symptom, but among patients with glioma, grade II epileptic seizures were the most frequent symptom. Headache was a rare mono-symptomatic onset symptom. At presentation, higher age, focal deficits and cognitive change for <3 months duration, and headache <1 month were significant independent indicators of high-grade gliomas. Younger age and epileptic seizures for more than 3 months were indicative for low-grade gliomas. Survival rates for glioma grade I-IV showed decreasing survival with increasing grade. Glioma grade I-IV showed high diversity regarding several demographic and clinical characteristics emphasizing the importance of individually tailored disease treatments and support.

Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population

“…It is more prevalent in males compared to females. Incidence of high-grade glioma tends to increase with age (Louis et al, 2016;Rasmussen et al, 2017;Ostrom et al, 2018). This was also described in our study with male patient predominance (male: female = 1.26: 1), the youngest mean age was in glioma grade I (14.71 years old) while the highest mean age was in grade IV (46.50 years old) and the most common diagnosis was Glioblastoma, IDH-wildtype, (31.13%).…”

“…Data from The Global Cancer Atlas showed that 5.323 people i n Indonesia were diagnosed with primary brain and central nervous system cancer in 2018. Gliomas are the most frequent among all primary brain tumors (Rasmussen et al, 2017;Bray et al, 2018). Glioma histological grading classification based on World Health Organization (WHO) was divided into 4 grades (grade I-IV).…”

Patients’ experiences and care needs during the diagnostic phase of an integrated brain cancer pathway: A case study

“…This was achieved; however, as shown in Table only a minor variation was achieved concerning the age difference. Still, this was anticipated as gliomas occur most frequently between 58–78 years of age (Rasmussen et al., ).…”

Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida

“…5 Common symptoms and side effects include seizure, nausea and vomiting, and headache. [6][7][8] To address the neurologic symptoms associated with glioma, patients are often prescribed glucocorticoids (levetiracetam followed by lacosamide or valproic acid are agents of choice); however, long-term steroid use may have adverse effects. 9 While standard management for grade III-IV tumorsmaximal safe resection followed by chemoradiation 10 -may be associated with temporary amelioration of symptoms, the majority of patients suffer declining functional and cognitive status as the tumor progresses.…”